NGM Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10849
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NGM Biopharmaceuticals Inc (NGM Bio) is a clinical-stage biopharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases. The company’s pipeline products include NGM282, NGM386, NGM395, NGM621, NGM313, NGM217 and NGM120. Its NGM313 is an agonistic antibody of the beta-klotho pathway and development candidate for the treatment of metabolic conditions such as type 2 diabetes, obesity and non-alcoholic steatohepatitis. NGM Bio’s NGM282 is an engineered protein variant of FGF19 for the treatment of non-alcoholic steatohepatitis and bile acid-related diseases. The company’s biologics platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.

NGM Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NGM Biopharma Raises USD106 Million in Series E Financing 10
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 11
NGM Biopharma Raises USD20.7 Million in Series D Financing 12
NGM Biopharma Raises US$50 Million In Series C Venture Financing 13
Partnerships 14
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16
Licensing Agreements 17
Ablexis Enters into Licensing Agreement with NGM Biopharma 17
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18
Equity Offering 19
NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19
NGM Biopharmaceuticals Inc – Key Competitors 20
NGM Biopharmaceuticals Inc – Key Employees 21
NGM Biopharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Corporate Communications 23
Oct 01, 2018: NGM Biopharmaceuticals names David J. Woodhouse as Chief Executive Officer and Aetna Wun Trombley as President and Chief Operating Officer 23
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
NGM Biopharma Raises USD106 Million in Series E Financing 10
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 11
NGM Biopharma Raises USD20.7 Million in Series D Financing 12
NGM Biopharma Raises US$50 Million In Series C Venture Financing 13
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 14
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 15
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 16
Ablexis Enters into Licensing Agreement with NGM Biopharma 17
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 18
NGM Biopharma Files Registration Statement to Raise up to USD75 Million IPO of Shares 19
NGM Biopharmaceuticals Inc, Key Competitors 20
NGM Biopharmaceuticals Inc, Key Employees 21

List of Figures
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[NGM Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Takara Standard Co.,Ltd. (7981):企業財務及び戦略的SWOT分析
    Summary Takara Standard Co.,Ltd. (Takara Standard) is a household equipment company that manufactures and sells system kitchens, system baths and washstands. The company’s products include enameled system kitchens, artificial marble bathtubs, system baths, enameled washstand, sink units, heating app …
  • T7 Global Berhad (T7GLOBAL):石油・ガス:M&Aディール及び事業提携情報
    Summary T7 Global Berhad (T7 Global), formerly Tanjung Offshore Berhad, is an oil and gas company that offers gas generators and integrated services. The company's services include topside maintenance, engineering and procurement, installation and commissioning, initial engineering design layout, pr …
  • KTandG Corporation:企業概要・SWOT・財務分析
    Summary Canadean's "KTandG Corporation : Consumer Packaged Goods - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business descr …
  • Midas Group Limitedの企業概要及びSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Midas Group Limited" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. World Market Intelligen …
  • Celltrion Healthcare Co Ltd (091990):製薬・医療:M&Aディール及び事業提携情報
    Summary Celltrion Healthcare Co Ltd (Celltrion) is engaged in distributing, marketing and selling of biosimilar and biological medicines. Its products include Remsima and Truxima. Remsima is a biosimilar monoclonal antibody medication used for autoimmune diseases, including Crohn's disease (CD), ulc …
  • Modern Water plc (MWG):企業概要、財務及び戦略的SWOT分析
    Summary Modern Water plc (Modern Water) is a water treatment company. The company owns, installs and operates membrane technologies, and develops and supplies systems for water monitoring. Its membrane process division utilizes forward osmosis technology for various membrane processes including desa …
  • Receptor BioLogix, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Receptor BioLogix, Inc. Mergers …
  • Johnson Controls, Inc. (JCI):企業の財務及び戦略的SWOT分析
    Johnson Controls, Inc. (JCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Reliance Capital Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Reliance Capital Limited Merger …
  • Godrej Industries Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Godrej Industries Limited Merge …
  • ActionView International, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ActionView International, Inc. …
  • IBC Solar AG:企業の戦略的SWOT分析
    IBC Solar AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • NuScale Power LLC-エネルギー分野:企業M&A・提携分析
    Summary NuScale Power, LLC (NuScale), a subsidiary of Fluor Enterprises, Inc., is an energy equipment provider that designs and develops small, light water, and modular nuclear reactors based on light water reactor technology. It offers carbon-free nuclear power through its NuScale Power Module (NPM …
  • Cogstate Limited (CGS):企業概要、財務及び戦略的SWOT分析
    Summary CogState Limited (CogState) is a cognitive science company. The company provides products and services in healthcare, clinical trials, sports and academic research. It concentrates on the development and commercialization of rapid, computerized tests of cognition (brain function). CogState’s …
  • Kinden Corporation (1944):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Kinden Corporation" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follow …
  • Encision Inc. (ECIA):企業概要、財務及び戦略的SWOT分析
    Summary Encision Inc. (Encision) is a surgical instrument provider. The company offers laparoscopic monopolar surgical instruments. Its products include AEM burn protection systems, AEM instrumentation, cord adapter, inhibit adapter extension, monitor setup, monitor alarms, monitor with universal ad …
  • Tandem Diabetes Care Inc (TNDM):企業の製品パイプライン分析2018
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device company that designs, develops and manufactures diabetic care products. The company provides products such as t:slim X2 insulin pump, t:slim G4 insulin pump, t:flex insulin pump, t:simulator demo app, software and apps, t:connect applicat …
  • Biesse S.p.A. (BSS):企業財務及び戦略的SWOT分析
    Summary Biesse S.p.A. (Biesse) is a woodworking machinery provider that offers machines and systems for processing wood, marble, and glass. The company offers products including rover, winline, selco, akron, stream, spark, viet, skipper, insider, bremen, techno, handling, and jade. It provides woodw …
  • Daikokutenbussan Co., Ltd. (2791):企業の財務及び戦略的SWOT分析
    Summary Daikokutenbussan Co., Ltd. (Daikokutenbussan) is a retailing company that offers consumer products. The company provides foodstuffs, fresh food, convenience goods, and other products in Japan. It also conducts wholesale activities. Daikokutenbussan offers consulting services for store develo …
  • Murree Brewery Company Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Murree Brewery Company Limited …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆